This live ancillary satellite symposium held in Chicago on Saturday, June 2, will feature a panel of expert faculty convened to explore some of the most promising new science to date on the JAK-STAT pathway and JAK inhibition. The event will pose and answer the question: Why should the practicing oncology professional be aware of the exciting early data on JAK inhibition across malignant settings? The experts will address this question head-on, and cover both the current, practical applications of JAK inhibition in myeloproliferative neoplasms before exploring cutting-edge research in leukemia, lymphoma, gastrointestinal cancers, and breast cancer.